Fast Five Quiz: Relapsed and Metastatic Renal Cell Carcinoma

Elwyn C. Cabebe, MD


July 08, 2022

The initial treatment of advanced or metastatic RCC is systemic therapy. Immune checkpoint inhibitors, either as a dual type (eg, nivolumab plus ipilimumab) or in combination with kinase inhibitors (eg, pembrolizumab plus axitinib), are standard of care treatment options. The selection of agents is based on disease-related symptoms, patient comorbidities, and tumor risk stratification. Combination immunotherapy has been accepted by guidelines following numerous studies demonstrating improvements in overall survival and progression-free survival. Single-agent immunotherapy may be an option for patients with favorable-risk tumors; however, immunotherapy-based combinations are preferred.

Interferon alpha has been replaced by immunotherapy with checkpoint inhibitors and targeted agents and is generally no longer used for the treatment of RCC.

An mTOR inhibitor in combination with a VEGF receptor inhibitor, such as lenvatinib plus everolimus, may be an option for intermediate- or poor-risk disease patients who are ineligible for immunotherapy or as second-line treatment.

Learn more about RCC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.